Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomized trials

International Journal of Clinical Pharmacology and Therapeutics

Volumn 41, Issue 12, 2003, Pages 567-577

  Vrecer, M ^a   Turk, S ^a   Drinovec, J ^a   Mrhar, Ales ^b  

^a University of Ljubljana ^*

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Cardiovascular disease; Meta analysis; Prevention; Stroke

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; ATORVASTATIN; BETA CAROTENE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COCHRANE LIBRARY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; DRUG EFFICACY; FEMALE; HUMAN; INFORMATION PROCESSING; ISCHEMIC HEART DISEASE; MALE; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; MORTALITY; PRIMARY PREVENTION; REVIEW; RISK ASSESSMENT; SAMPLE SIZE; SECONDARY PREVENTION; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0346872978     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP41567     Document Type: Review

References (50)

1. Altman DG 1998 Confidence intervals for the number needed to treat. BMJ 317: 1309-1312
2. Blankenhorn DH, Azen SP, Kramsch DM et al 1993 Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 119: 969-976
3. Blauw GJ, Lagaay AM, Smelt AHM et al 1997 Stroke, statins and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke 28: 946-950
4. Bradford RH, Shear CL, Chremos AN et al 1990 Expanded Clinical Evaluation of Lovastatin (EXCEL) Study: Design and patient characteristics of a double-blind, placebo-controlled study in patients with moderate hypercholesterolemia. Am J Cardiol 66: 44B-55B
5. Bradford RH, Shear CL, Chremos AN et al 1991 Expanded Clinical Evaluation of Lovastatin (EXCEL) Study results. Efficacy in modifying plasma lipoproteins and adverse event profile in 8,245 patients with moderate hypercholesterolemia. Arch Intern Med 151: 43-49
6. Byington RP, Davis BR, Plehn JF et al 2001 Reduction of stroke events with pravastatin. The Prospective Pravastatin Pooling (PPP) Project. Circulation 103: 387-392
7. Castelli WP, Anderson K, Wilson PWF et al 1992 Lipids and risk of coronary heart disease. The Framingham Study. Ann Epidemiol 2: 23-28
8. Cleophas TJ, Zwinderman AH 2001 Beta-blockers and heart failure: meta-analysis of mortality trials. Int J Clin Pharmacol Ther 39: 383-388
9. Collins R, Peto R, Armitage J 2002 The MRC/BHF Heart Protection Study: preliminary results. Int J Clin Pract 56: 53-56
10. Crouse JR, Bond MG, Sprinkle JW et al 1992 Pravastatin, lipids and atherosclerosis in the carotid arteries: design features of a clinical trial with carotid atherosclerosis outcome. Contr Clin Trials 13: 495-506
11. Crouse JR, Byington RP, Bond MG et al 1995 Pravastatin, lipids and atherosclerosis in the carotid arteries (PLAC II). Am J Cardiol 75: 455-459
12. Crouse JR, Byington RP, Holn HM et al 1997 Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med 157: 1305-1310
13. Di Mascio R, Marchioli R, Tognoni G 2000 Cholesterol reduction and stroke occurrence: an overview of randomized clinical trials. Cerebrovasc Dis 10: 85-92
14. Downs JR, Clearfield M, Weiss S et al 1998 Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 279: 1615-1622
15. Dumont JM 1993 Effect of cholesterol reduction by simvastatin on progression of coronary atherosclerosis: design, baseline characteristics and progress of the Multicenter Anti-Atheroma Study (MAAS). Contr Clin Trials 14: 209-228
16. Egger M, Smith GD, Philips AN 1997 Meta-analysis: principles and procedures. BMJ 315: 1533-1537
17. Furberg CD, Byington RP, Crouse JR et al 1994a Pravastatin, lipids and major coronary events. Am J Cardiol 73: 1133-1134
18. Furberg CD, Adans HP, Applegate WB et al for the Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group 1994b Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation 90: 1679-1687
19. Heart Protection Study Collaborative Group 1999 MRC/BHC Heart protection study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. Eur Heart J 20: 725-741
20. Heart Protection Study Collaborative Group 2002 MRC/BHC Heart protection study of cholesterol-lowering with simvastatin in 20,536 high-risk individuals: a randomized, placebo-controlled trial. Lancet 360: 7-22
21. Hebert PR, Gaziano JM, Chan KS et al 1997 Cholesterol-lowering with statin drugs, risk of stroke and total mortality. An overview of randomized trials. JAMA 278: 313-321
22. Jukema JW, Brusche AVG, van Boven AJ et al 1995 Effects of lipid-lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal-to-moderately elevated serum cholesterol levels: the Regression Growth Evaluation Study (REGRESS). Circulation 91: 2528-2540
23. Kuss O, Koch A 1996 Meta-analysis macros for SAS. Statistical Software Newsletter 22: 325-333
24. LaRosa JC, He J, Vupputuri S 1999 Effects of statins on risk of coronary disease. A meta-analysis of randomized controlled trials. JAMA 282: 2340-2346
25. Lesaffre E, Pledger G 1999 A note on the number needed to be treat-controlled. Clin Trials 20: 439-447
26. Levy D, Wilson PWF, Anderson KM et al 1990 Stratifying the patient at risk from coronary disease: new insights from the Framingham Heart Study. Am Heart J 119: 712-717
27. Lipid Research Clinics Program 1984a The Lipid Research Vlinics Coronary Primary Prevention Trial Results. I. Reduction in incidence of coronary heart disease. JAMA 251: 351-364
28. Lipid Research Clinics Program 1984b The Lipid Research Clinics Coronary Primary Prevention Trial Results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251: 365-374
29. Lipid Study Group 1998 Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 19: 1349-1357
30. MAAS Investigators 1994 Effect of simvastatin on coronary atheroma: the Multicenter Anti-Atheroma Study (MAAS). Lancet 344: 633-638
31. Normand ST 1999 Tutorial in biostatistics meta-analysis: formulating, evaluating, combining and reporting. Stat Med 18: 321-359
32. Petitti DM 1994 Meta-analysis, decision analysis and cost effectiveness analysis methods for quantitative synthesis in medicine. Oxford University Press, New York
33. Pignone M, Philips C, Mulrow C 2000 Use of lipid-lowering drugs for primary prevention of coronary heart disease: a meta-analysis of randomized trials. BMJ 321: 1-5
34. Pitt B, Mancini J, Ellis SG et al 1995 Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol 26: 1133-1139
35. Plehn JF, Davis BR, Sacks FM et al 1999 Reduction of stroke incidence after myocardial infarction with pravastatin. The Cholesterol and Recurrent Events (CARE) Study. Circulation 99: 216-223
36. Prospective Studies Collaboration 1995 Cholesterol, diastolic blood pressure and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet 346: 1647-1653
37. Ridker PM, Rifai N, Pfefer MA et al 1999 Inflammation, pravastatin and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 98: 839-844
38. Ross SD, Allen E, Connelly JE et al 1999 Clinical outcomes in statin treatment trials. A meta-analysis. Arch Intern Med 159: 1793-1802
39. Salonen R, Nyyssönen K, Porkkala E et al 1995 Kuopio Atherosclerosis Prevention Study (KAPS): a population-based primary prevention trial of the effect of LDL-lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 92: 1758-1764
40. Scandinavian Simvastatin Survival Study Group 1994 Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389
41. Scandinavian Simvastatin Survival Study Group 1995 Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 345: 1274-1275
42. Shear CL, Franklin FA, Stinnett S et al 1992 Expanded Clinical Evaluation of Lovastatin (EXCEL) Study results. Effect of patient characteristics on lovastatin-induced changes in plasma concentrations of lipids and lipoproteins. Circulation 85: 1293-1303
43. Sirol M, Bouzamondo A, Sancez P et al 2001 Les Statines Prévinnent-elles le risque d'accident vasculaire cérébral? Ann Med Interne 152: 188-193
44. Skolbekken JA 1998 Communicating the risk reduction achieved by cholesterol-reducing drugs. BMJ 316: 1956-1958
45. Stamler J, Wentworth D, Neaton JD 1986 Is relationship between serum cholesterol and risk of premature death from coronary hearth disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 256: 2823-2828
46. Wang MC, Bushman BJ 1999 Integrating results through meta-analysis reviews using SAS Software. SAS Institute, Cary, NC, USA
47. Warshafsky S, Packard D, Marks S et al 1999 Efficacy of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors for prevention of stroke. J Gen Intern Med 14: 763-774
48. Waters D, Higginson L, Gladstone P et al 1993 Design features of a controlled clinical trial to asses the effect of an HMG-CoA reductase inhibitor on the progression of coronary artery disease. Contr Clin Trials 14: 45-74
49. Waters D, Higginson L, Gladstone P et al 1994 Effects of monotherapy with HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 89: 959-968
50. West of Scotland Coronary Prevention Study Group 1998 Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 97: 1440-1445